IGI Logo

Below is quote on Dr. Reddy’s Laboratories reported Q2FY22 numbers by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd   

Dr. Reddy’s Laboratories reported Q2FY22 numbers better than the market expectation.

Dr. Reddy’s Laboratories Limited reported revenue from operation at ₹5,763 crores up by 18% YoY from ₹4,896 crores in Q2FY21, the domestic market has reported revenue growth of 25% at ₹1,140.2 crores and emerging market up by 50% at ₹1,298 crores while North America market up by only 3%. Company reported Gross Margins of 53.4%, flat YoY. Company reported EBITDA margins of 27% up by 110 bps and EBITDA at ₹1,556. Company reported a net profit of ₹992 crores up by 30% as compared to ₹762.3 crores in Q2FY21.

Dr. Reddy’s Laboratories reported numbers better than the market expectation, domestic business has done well for the company this quarter along with the emerging market. This quarter also we have seen some pressure in the north america market while API business reported degrowth of 2%. Overall margins are better than the market expectation. We have a neutral outlook on Dr. Reddy’s Laboratories.

Above views are of the author and not of the website kindly read disclaimer